Group structure
6 companies in 3 countries
Loading your pageโฆ
Loading your pageโฆ
6 companies in 3 countries
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
1โ25 of 88
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ABIRATERONA QILU 250 MG COMPRIMIDOS EFG250 mg ยท Comprimido | Abiraterone | Spain | Authorised | 2022 |
| ABIRATERONA QILU 500 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFG500 mg ยท Comprimido recubierto con pelรญcula | Abiraterone | Spain | Marketed | 2023 |
| ABIRATERONE QILUCompressa rivestita con film | Abiraterone | Italy | Authorised | |
| APREPITANT QILU 125 MG CAPSULAS DURAS/ APREPITANT QILU 80 MG CAPSULAS DURAS EFG80 mg + 125 mg ยท Cรกpsula dura | Aprepitant | Spain | Authorised | 2021 |
| APREPITANT QILU 125 MG CAPSULAS DURAS EFG125 mg ยท Cรกpsula dura | Aprepitant | Spain | Authorised | 2021 |
| APREPITANT QILU 80 MG CAPSULAS DURAS EFG80 mg ยท Cรกpsula dura | Aprepitant | Spain | Authorised | 2021 |
| BORTEZOMIB QILUSoluzione iniettabile | Bortezomib | Italy | Authorised | |
| BORTEZOMIB QILU 2,5 MG/ML SOLUCION INYECTABLE2,5 mg/ml ยท Soluciรณn inyectable | Bortezomib | Spain | Authorised | 2024 |
| BUMETANIDE0.25mg/ml ยท Injectable | Bumetanide | United States | Marketed | 1994 |
| Cefazolin Qilu 1 g praลกak za otopinu za injekciju/infuzijuPraลกak za otopinu za injekciju / infuziju | Cefazolin | Croatia | Marketed | 2023 |
| CEFAZOLINA QILUPolvere per soluzione iniettabile/per infusione | Cefazolin | Italy | Authorised | |
| CEFAZOLINA QILU 1 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG1.048 g ยท Polvo para soluciรณn inyectable y para perfusiรณn | Cefazolin | Spain | Marketed | 2018 |
| CEFAZOLINA QILU 2 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG2.097 g ยท Polvo para soluciรณn inyectable y para perfusiรณn | Cefazolin | Spain | Marketed | 2018 |
| CEFEPIMA QILU 1 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG1.189 g ยท Polvo para soluciรณn inyectable y para perfusiรณn | Cefepima dihidrocloruro | Spain | Marketed | 2019 |
| CEFEPIMA QILU 2 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG2.378 g ยท Polvo para soluciรณn inyectable y para perfusiรณn | Cefepima dihidrocloruro | Spain | Marketed | 2019 |
| CEFEPIME FOR INJECTION, USP1 g / vial ยท Powder For Solution | Cefepime | Canada | Authorised | |
| CEFEPIME FOR INJECTION, USP2 g / vial ยท Powder For Solution | Cefepime | Canada | Authorised | |
| CEFEPIME QILUPolvere per soluzione iniettabile/per infusione | Cefepime | Italy | Authorised | |
| CEFTAROLINA FOSAMIL QILUPolvere per concentrato e soluzione per soluzione per infusione | Ceftaroline fosamil | Italy | Authorised | |
| CEFTAROLINA FOSAMILO QILU 600 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION EFG600 mg ยท Polvo para concentrado para soluciรณn para perfusiรณn | Ceftaroline fosamil | Spain | Marketed | 2025 |
| CEFTAZIDIMA QILUSoluzione iniettabile | Ceftazidime | Italy | Authorised | |
| CEFTAZIDIMA QILU 1 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG1165 mg ยท Polvo para soluciรณn inyectable y para perfusiรณn | Ceftazidime | Spain | Marketed | 2019 |
| CEFTAZIDIMA QILU 2 G POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG2330 mg ยท Polvo para soluciรณn inyectable y para perfusiรณn | Ceftazidime | Spain | Marketed | 2019 |
| Ceftriakson Qilu 1 g praลกak za otopinu za injekciju/infuzijuPraลกak za otopinu za injekciju / infuziju | Ceftriaxone | Croatia | Marketed | 2022 |
| Ceftriakson Qilu 2 g praลกak za otopinu za injekciju/infuzijuPraลกak za otopinu za injekciju / infuziju | Ceftriaxone | Croatia | Marketed | 2022 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 52 | 50 | 2 | CompaniesAll medicines |
| Italy | 14 | 14 | 0 | CompaniesAll medicines |
| Croatia | 9 | 9 | 0 | CompaniesAll medicines |
| United States | 6 | 4 | 2 | CompaniesAll medicines |
| Netherlands | 3 | 3 | 0 | CompaniesAll medicines |
| Canada | 2 | 2 | 0 | CompaniesAll medicines |
| European Union (EMA) | 1 | 1 | 0 | CompaniesAll medicines |
| Saudi Arabia | 1 | 1 | 0 | CompaniesAll medicines |
Also in the registers of Brazil, France, Singapore, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la informaciรณn: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la informaciรณn: Agencia Espaรฑola de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la informaciรณn: Agencia Espaรฑola de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 2 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:48.423930+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
HALMED, Baza lijekova, source export 08.10.2026., acquired 2026-10-08; factual structured adaptation; Otvorena dozvola RH, NN 67/2017.
Licence: Otvorena dozvola RH
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Saudi Food and Drug Authority (SFDA), foreign human medicine open-data listing, source scope 2023, retrieved 11 October 2026 UTC; exact original file and response modification date retained.
Licence: Exact SFDA open-data section explicitly offers freely usable named human medicine workbooks; factual-data scope only
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
Report an error or request removalCorrections from the company itself are welcome.
Well-known pharmaceutical groups, each with all its companies.